TBC1D4 antibody is a tool used to detect TBC1D4. a protein encoded by the *TBC1D4* gene, also known as AS160 (Akt substrate of 160 kDa). TBC1D4 belongs to the TBC (Tre-2/Bub2/Cdc16) family of Rab GTPase-activating proteins (GAPs), which regulate intracellular vesicle trafficking and signal transduction. It plays a critical role in insulin-stimulated glucose uptake by controlling the translocation of glucose transporter GLUT4 to the plasma membrane in adipocytes and skeletal muscle cells. Phosphorylation of TBC1D4 by Akt/PKB during insulin signaling inactivates its Rab GAP activity, enabling GLUT4 vesicle mobilization. Dysregulation of TBC1D4 is linked to insulin resistance, type 2 diabetes, and obesity.
The TBC1D4 antibody is widely used in research to study its expression, post-translational modifications (e.g., phosphorylation at Ser-588 or Thr-642), and interactions in metabolic pathways. It aids in detecting TBC1D4 via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Commercial antibodies are typically raised in hosts like rabbits or mice, targeting specific epitopes within the protein’s N-terminal phosphotyrosine-binding (PTB) domain or C-terminal regions.
Mutations in *TBC1D4* are associated with severe insulin resistance syndromes and metabolic disorders, making the antibody a valuable tool for mechanistic studies and potential diagnostic applications. Research using TBC1D4 antibodies has advanced understanding of glucose homeostasis, insulin signaling defects, and therapeutic targets for metabolic diseases.